Multiple sclerosis: molecular pathogenesis and therapeutic intervention
Top Cited Papers
Open Access
- 2 October 2025
- journal article
- review article
- Published by Springer Nature in Signal Transduction and Targeted Therapy
- Vol. 10 (1) , 1-40
Abstract
Multiple sclerosis is a chronic immune-mediated disorder of the central nervous system characterized by demyelination, axonal loss, and neuroinflammation, culminating in progressive neurological disability. Despite significant advances in understanding its immunopathogenesis, current immunotherapies remain limited in their ability to halt disease progression, making multiple sclerosis incurable and highlighting the critical need for novel therapeutic strategies. Antigen-specific immunotherapy represents a groundbreaking approach that aims to restore immune tolerance to myelin-derived antigens while preserving the protective functions of the immune system. Unlike broad immunosuppressive strategies, antigen-specific immunotherapy offers the potential for highly targeted modulation of pathogenic immune responses, reducing off-target effects and enhancing safety profiles. Over the last two decades, preclinical studies and clinical trials have explored diverse antigen-specific immunotherapy modalities, ranging from peptide-based vaccines to nanoparticle platforms, each aimed at achieving durable tolerance in multiple sclerosis. This review provides a comprehensive overview of multiple sclerosis, covering its etiology, clinical features, pathogenesis, pathology, and current therapeutic approaches. Thus, it delves into the current state of antigen-specific immunotherapy research, critically examining its successes and limitations while addressing the translational challenges that must be overcome to realize its therapeutic potential. By integrating insights from immunology, biotechnology, and translational medicine, we propose directions for advancing antigen-specific approaches in the quest for transformative multiple sclerosis therapies.Keywords
This publication has 547 references indexed in Scilit:
- Spreading of T-cell autoimmunity to cryptic determinants of an autoantigenNature, 1992
- Immunological Aspects of Demyelinating DiseasesAnnual Review of Immunology, 1992
- Studies of Vβ8 T cell receptor peptide treatment in experimental autoimmune encephalomyelitisJournal of Neuroimmunology, 1992
- Antigen-specific therapy of experimental allergic encephalomyelitis by soluble class II major histocompatibility complex-peptide complexes.Proceedings of the National Academy of Sciences, 1991
- A single amino acid change in a myelin basic protein peptide confers the capacity to prevent rather than induce experimental autoimmune encephalomyelitis.Proceedings of the National Academy of Sciences, 1991
- T Cell Receptor Peptide Therapy Triggers Autoregulation of Experimental EncephalomyelitisScience, 1991
- Inhibition of murine relapsing experimental autoimmune encephalomyelitis by immune tolerance to proteolipid protein and its encephalitogenic peptides.The Journal of Immunology, 1990
- Susceptibility to PLP‐Induced EAE Is Regulated by Non‐H‐2 GenesaAnnals of the New York Academy of Sciences, 1988
- Suppression of experimental autoimmune encephalomyelitis by oral administration of myelin basic protein and its fragments.The Journal of Immunology, 1988
- T-cell epitope of the autoantigen myelin basic protein that induces encephalomyelitisNature, 1986